Literature DB >> 31987492

Medication for Attention-Deficit/Hyperactivity Disorder and Risk for Suicide Attempts.

Zheng Chang1, Patrick D Quinn2, Lauren O'Reilly3, Arvid Sjölander4, Kwan Hur5, Robert Gibbons5, Henrik Larsson6, Brian M D'Onofrio7.   

Abstract

BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is a risk factor for suicidal behavior, but the effect of ADHD medication on suicidal behavior remains unclear. This study aimed to examine the associations between medication treatment for ADHD and risk of suicide attempts.
METHODS: We identified a large cohort of patients with ADHD (N = 3,874,728, 47.8% female patients) using data from commercial health care claims from 2005 to 2014 in the United States. We used population-level and within-individual analyses to compare risk of suicide attempts during months when individuals received prescribed stimulant or nonstimulant medication relative to months when they did not receive medication.
RESULTS: In both population-level and within-individual analyses, ADHD medication was associated with lower odds of suicide attempts (odds ratio [OR], 0.69; 95% confidence interval [CI], 0.66-0.73; and OR, 0.61; 95% CI, 0.57-0.66, respectively). Similar reductions were found in children to middle-aged adults and in clinically relevant subgroups, including patients with ADHD with preexisting depression or substance use disorder. The reduction was mainly seen for stimulant medication (OR, 0.72; 95% CI, 0.66-0.77); nonstimulant medication was not associated with statistically significant changes in risk of suicide attempts (OR, 0.94; 95% CI, 0.74-1.19). Sensitivity analyses assessing the influence of different exposure definitions, different outcome definitions, subsets of the cohort, and different analytic approaches provided comparable results.
CONCLUSIONS: Stimulant medication was associated with a reduced risk of suicide attempts in patients with ADHD, and nonstimulant medication is unlikely to increase the risk of suicide attempts.
Copyright © 2019 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ADHD; ADHD medication; Cohort study; Real-world evidence; Stimulants; Suicide attempt

Mesh:

Substances:

Year:  2019        PMID: 31987492      PMCID: PMC7292769          DOI: 10.1016/j.biopsych.2019.12.003

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  25 in total

1.  Rethinking impulsivity in suicide.

Authors:  E David Klonsky; Alexis May
Journal:  Suicide Life Threat Behav       Date:  2010-12

2.  Prevalence and Correlates of Prescription Stimulant Use, Misuse, Use Disorders, and Motivations for Misuse Among Adults in the United States.

Authors:  Wilson M Compton; Beth Han; Carlos Blanco; Kimberly Johnson; Christopher M Jones
Journal:  Am J Psychiatry       Date:  2018-04-16       Impact factor: 18.112

Review 3.  Adult ADHD and suicide.

Authors:  Karolina Furczyk; Johannes Thome
Journal:  Atten Defic Hyperact Disord       Date:  2014-07-26

4.  Use of atomoxetine and suicidal ideation in children and adolescents: Results of an observational cohort study within general practice in England.

Authors:  M Davies; A Coughtrie; D Layton; S A S Shakir
Journal:  Eur Psychiatry       Date:  2016-11-01       Impact factor: 5.361

Review 5.  Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis.

Authors:  Rae Thomas; Sharon Sanders; Jenny Doust; Elaine Beller; Paul Glasziou
Journal:  Pediatrics       Date:  2015-03-02       Impact factor: 7.124

6.  Association of Risk of Suicide Attempts With Methylphenidate Treatment.

Authors:  Kenneth K C Man; David Coghill; Esther W Chan; Wallis C Y Lau; Chris Hollis; Elizabeth Liddle; Tobias Banaschewski; Suzanne McCarthy; Antje Neubert; Kapil Sayal; Patrick Ip; Martijn J Schuemie; Miriam C J M Sturkenboom; Edmund Sonuga-Barke; Jan Buitelaar; Sara Carucci; Alessandro Zuddas; Hanna Kovshoff; Peter Garas; Peter Nagy; Sarah K Inglis; Kerstin Konrad; Alexander Häge; Eric Rosenthal; Ian C K Wong
Journal:  JAMA Psychiatry       Date:  2017-10-01       Impact factor: 21.596

7.  Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder.

Authors:  J Fayyad; R De Graaf; R Kessler; J Alonso; M Angermeyer; K Demyttenaere; G De Girolamo; J M Haro; E G Karam; C Lara; J-P Lépine; J Ormel; J Posada-Villa; A M Zaslavsky; R Jin
Journal:  Br J Psychiatry       Date:  2007-05       Impact factor: 9.319

Review 8.  Adult attention-deficit hyperactivity disorder: key conceptual issues.

Authors:  Philip Asherson; Jan Buitelaar; Stephen V Faraone; Luis A Rohde
Journal:  Lancet Psychiatry       Date:  2016-05-13       Impact factor: 27.083

Review 9.  The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.

Authors:  Victoria A Reed; Jan K Buitelaar; Ernie Anand; Kathleen Ann Day; Tamás Treuer; Himanshu P Upadhyaya; David R Coghill; Ludmila A Kryzhanovskaya; Nicola C Savill
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

10.  Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study.

Authors:  Qi Chen; Arvid Sjölander; Bo Runeson; Brian M D'Onofrio; Paul Lichtenstein; Henrik Larsson
Journal:  BMJ       Date:  2014-06-18
View more
  6 in total

1.  Investigating the causal risk factors for self-harm by integrating Mendelian randomisation within twin modelling.

Authors:  Kai Xiang Lim; Olakunle Ayokunmi Oginni; Kaili Rimfeld; Jean-Baptiste Pingault; Frühling Rijsdijk
Journal:  Behav Genet       Date:  2022-09-14       Impact factor: 2.965

2.  Identification of shared and differentiating genetic architecture for autism spectrum disorder, attention-deficit hyperactivity disorder and case subgroups.

Authors:  Manuel Mattheisen; Jakob Grove; Thomas D Als; Joanna Martin; Georgios Voloudakis; Sandra Meier; Ditte Demontis; Jaroslav Bendl; Raymond Walters; Caitlin E Carey; Anders Rosengren; Nora I Strom; Mads Engel Hauberg; Biao Zeng; Gabriel Hoffman; Wen Zhang; Jonas Bybjerg-Grauholm; Marie Bækvad-Hansen; Esben Agerbo; Bru Cormand; Merete Nordentoft; Thomas Werge; Ole Mors; David M Hougaard; Joseph D Buxbaum; Stephen V Faraone; Barbara Franke; Søren Dalsgaard; Preben B Mortensen; Elise B Robinson; Panos Roussos; Benjamin M Neale; Mark J Daly; Anders D Børglum
Journal:  Nat Genet       Date:  2022-09-26       Impact factor: 41.307

3.  Risk factors for pre-adolescent onset suicidal behavior in a high-risk sample of youth.

Authors:  Jamie Zelazny; Barbara Stanley; Giovanna Porta; J John Mann; Maria Oquendo; Boris Birmaher; Nadine Melhem; David A Brent
Journal:  J Affect Disord       Date:  2021-05-05       Impact factor: 6.533

4.  Associations of opioid prescription dose and discontinuation with risk of substance-related morbidity in long-term opioid therapy.

Authors:  Patrick D Quinn; Zheng Chang; Matthew J Bair; Martin E Rickert; Robert D Gibbons; Kurt Kroenke; Brian M D'Onofrio
Journal:  Pain       Date:  2022-04-01       Impact factor: 7.926

Review 5.  Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review.

Authors:  Rafał R Jaeschke; Ewelina Sujkowska; Magdalena Sowa-Kućma
Journal:  Psychopharmacology (Berl)       Date:  2021-08-26       Impact factor: 4.530

6.  Mainstreaming adult ADHD into primary care in the UK: guidance, practice, and best practice recommendations.

Authors:  Philip Asherson; Laurence Leaver; Marios Adamou; Muhammad Arif; Gemma Askey; Margi Butler; Sally Cubbin; Tamsin Newlove-Delgado; James Kustow; Jonathan Lanham-Cook; James Findlay; Judith Maxwell; Peter Mason; Helen Read; Kobus van Rensburg; Ulrich Müller-Sedgwick; Jane Sedgwick-Müller; Caroline Skirrow
Journal:  BMC Psychiatry       Date:  2022-10-11       Impact factor: 4.144

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.